1
|
Pillai RS, Bhattacharyya SN and Filipowicz
W: Repression of protein synthesis by miRNAs: How many mechanisms?
Trends Cell Biol. 17:118–126. 2007. View Article : Google Scholar : PubMed/NCBI
|
2
|
Peters L and Meister G: Argonaute
proteins: Mediators of RNA silencing. Mol Cell. 26:611–623. 2007.
View Article : Google Scholar : PubMed/NCBI
|
3
|
Wu CL, Ho JY, Chou SC and Yu DS: MiR-429
reverses epithelial-mesenchymal transition by restoring E-cadherin
expression in bladder cancer. Oncotarget. 7:26593–26603.
2016.PubMed/NCBI
|
4
|
Liang HQ, Wang RJ, Diao CF, Li JW, Su JL
and Zhang S: The PTTG1-targeting miRNAs miR-329, miR-300, miR-381,
and miR-655 inhibit pituitary tumor cell tumorigenesis and are
involved in a p53/PTTG1 regulation feedback loop. Oncotarget.
6:29413–29427. 2015. View Article : Google Scholar : PubMed/NCBI
|
5
|
Manikandan M, Deva Magendhra Rao AK,
Arunkumar G, Manickavasagam M, Rajkumar KS, Rajaraman R and
Munirajan AK: Oral squamous cell carcinoma: MicroRNA expression
profiling and integrative analyses for elucidation of
tumourigenesis mechanism. Mol Cancer. 15:282016. View Article : Google Scholar : PubMed/NCBI
|
6
|
Jiang W, Tian Y, Jiang S, Liu S, Zhao X
and Tian D: MicroRNA-376c suppresses non-small-cell lung cancer
cell growth and invasion by targeting LRH-1-mediated Wnt signaling
pathway. Biochem Biophys Res Commun. 473:980–986. 2016. View Article : Google Scholar : PubMed/NCBI
|
7
|
Wang RJ, Li JW, Bao BH, Wu HC, Du ZH, Su
JL, Zhang MH and Liang HQ: MicroRNA-873 (miRNA-873) inhibits
glioblastoma tumorigenesis and metastasis by suppressing the
expression of IGF2BP1. J Biol Chem. 290:8938–8948. 2015. View Article : Google Scholar : PubMed/NCBI
|
8
|
Renjie W and Haiqian L: MiR-132, miR-15a
and miR-16 synergistically inhibit pituitary tumor cell
proliferation, invasion and migration by targeting Sox5. Cancer
Lett. 356:568–578. 2015. View Article : Google Scholar : PubMed/NCBI
|
9
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
10
|
Jemal A, Tiwari RC, Murray T, Ghafoor A,
Samuels A, Ward E, Feuer EJ and Thun MJ; American Cancer Society, :
Cancer statistics, 2004. CA Cancer J Clin. 54:8–29. 2004.
View Article : Google Scholar : PubMed/NCBI
|
11
|
Zhang G, Hou X, Li Y and Zhao M: MiR-205
inhibits cell apoptosis by targeting phosphatase and tensin homolog
deleted on chromosome ten in endometrial cancer Ishikawa cells. BMC
Cancer. 14:4402014. View Article : Google Scholar : PubMed/NCBI
|
12
|
Wang Y, Adila S, Zhang X, Dong Y, Li W,
Zhou M and Li T: MicroRNA expression signature profile and its
clinical significance in endometrioid carcinoma. Zhonghua Bing Li
Xue Za Zhi. 43:88–94. 2014.(In Chinese). PubMed/NCBI
|
13
|
Kong X, Xu X, Yan Y, Guo F, Li J, Hu Y,
Zhou H and Xun Q: Estrogen regulates the tumour suppressor
MiRNA-30c and its target gene, MTA-1, in endometrial cancer. PLoS
One. 9:e908102014. View Article : Google Scholar : PubMed/NCBI
|
14
|
Konno Y, Dong P, Xiong Y, Suzuki F, Lu J,
Cai M, Watari H, Mitamura T, Hosaka M and Hanley SJ: MicroRNA-101
targets EZH2, MCL-1 and FOS to suppress proliferation, invasion and
stem cell-like phenotype of aggressive endometrial cancer cells.
Oncotarget. 5:6049–6062. 2014. View Article : Google Scholar : PubMed/NCBI
|
15
|
Ye W, Xue J, Zhang Q, Li F, Zhang W, Chen
H, Huang Y and Zheng F: MiR-449a functions as a tumor suppressor in
endometrial cancer by targeting CDC25A. Oncol Rep. 32:1193–1199.
2014. View Article : Google Scholar : PubMed/NCBI
|
16
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
17
|
Cohn DE, Fabbri M, Valeri N, Alder H,
Ivanov I, Liu CG, Croce CM and Resnick KE: Comprehensive miRNA
profiling of surgically staged endometrial cancer. Am J Obstet
Gynecol. 202(656): e651–658. 2010.
|
18
|
Lee II, Maniar K, Lydon JP and Kim JJ: Akt
regulates progesterone receptor B-dependent transcription and
angiogenesis in endometrial cancer cells. Oncogene. 35:5191–5201.
2016. View Article : Google Scholar : PubMed/NCBI
|
19
|
Zhang X, Choi PS, Francis JM, Imielinski
M, Watanabe H, Cherniack AD and Meyerson M: Identification of
focally amplified lineage-specific super-enhancers in human
epithelial cancers. Nat Genet. 48:176–182. 2016. View Article : Google Scholar : PubMed/NCBI
|
20
|
Zhao X, Zhu D, Lu C, Yan D, Li L and Chen
Z: MicroRNA-126 inhibits the migration and invasion of endometrial
cancer cells by targeting insulin receptor substrate 1. Oncol Lett.
11:1207–1212. 2016. View Article : Google Scholar : PubMed/NCBI
|
21
|
Devor EJ, Schickling BM, Reyes HD, Warrier
A, Lindsay B, Goodheart MJ, Santillan DA and Leslie KK: Cullin-5, a
ubiquitin ligase scaffold protein, is significantly underexpressed
in endometrial adenocarcinomas and is a target of miR-182. Oncol
Rep. 35:2461–2465. 2016. View Article : Google Scholar : PubMed/NCBI
|
22
|
Bai R, Weng C, Dong H, Li S, Chen G and Xu
Z: MicroRNA-409-3p suppresses colorectal cancer invasion and
metastasis partly by targeting GAB1 expression. Int J Cancer.
137:2310–2322. 2015. View Article : Google Scholar : PubMed/NCBI
|
23
|
Liu M, Xu A, Yuan X, Zhang Q, Fang T, Wang
W and Li C: Downregulation of microRNA-409-3p promotes
aggressiveness and metastasis in colorectal cancer: An indication
for personalized medicine. J Transl Med. 13:1952015. View Article : Google Scholar : PubMed/NCBI
|
24
|
Wan L, Zhu L, Xu J, Lu B, Yang Y, Liu F
and Wang Z: MicroRNA-409-3p functions as a tumor suppressor in
human lung adenocarcinoma by targeting c-Met. Cell Physiol Biochem.
34:1273–1290. 2014. View Article : Google Scholar : PubMed/NCBI
|
25
|
Zheng B, Liang L, Huang S, Zha R, Liu L,
Jia D, Tian Q, Wang Q, Wang C, Long Z, et al: MicroRNA-409
suppresses tumour cell invasion and metastasis by directly
targeting radixin in gastric cancers. Oncogene. 31:4509–4516. 2012.
View Article : Google Scholar : PubMed/NCBI
|
26
|
Josson S, Gururajan M, Hu P, Shao C, Chu
GY, Zhau HE, Liu C, Lao K, Lu CL, Lu YT, et al: miR-409-3p/-5p
promotes tumorigenesis, epithelial-to-mesenchymal transition, and
bone metastasis of human prostate cancer. Clin Cancer Res.
20:4636–4646. 2014. View Article : Google Scholar : PubMed/NCBI
|
27
|
Josson S, Gururajan M, Sung SY, Hu P, Shao
C, Zhau HE, Liu C, Lichterman J, Duan P, Li Q, et al: Stromal
fibroblast-derived miR-409 promotes epithelial-to-mesenchymal
transition and prostate tumorigenesis. Oncogene. 34:2690–2699.
2015. View Article : Google Scholar : PubMed/NCBI
|
28
|
Zhao JL, Zhang L, Guo X, Wang JH, Zhou W,
Liu M, Li X and Tang H: miR-212/132 downregulates SMAD2 expression
to suppress the G1/S phase transition of the cell cycle and the
epithelial to mesenchymal transition in cervical cancer cells.
IUBMB Life. 67:380–394. 2015. View
Article : Google Scholar : PubMed/NCBI
|
29
|
Bao Y, Chen Z, Guo Y, Feng Y, Li Z, Han W,
Wang J, Zhao W, Jiao Y, Li K, et al: Tumor suppressor microRNA-27a
in colorectal carcinogenesis and progression by targeting SGPP1 and
Smad2. PLoS One. 9:e1059912014. View Article : Google Scholar : PubMed/NCBI
|
30
|
Yang Y, Liu L, Cai J, Wu J, Guan H, Zhu X,
Yuan J, Chen S and Li M: Targeting Smad2 and Smad3 by miR-136
suppresses metastasis-associated traits of lung adenocarcinoma
cells. Oncol Res. 21:345–352. 2013. View Article : Google Scholar : PubMed/NCBI
|